Clinical trial
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
NCT00328523 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00328523 |
|---|---|
| Title | TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060) |
| Official title | Ezetimibe Together With Any Statin Cholesterol Enhancement |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesterolaemia, Hyperlipidaemia |
| Intervention type | Drug |
| Interventions | MK-0653, ezetimibe, Duration of Treatment: 3 months |
| Enrollment | 1,496 |
| Start date | Jun 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | May 22, 2006 |
| Last update posted | Aug 15, 2024 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: